Drug Profile
PT 00114
Alternative Names: PT-00114; PT100114Latest Information Update: 15 Apr 2024
Price :
$50
*
At a glance
- Originator Protagenic Therapeutics
- Developer Charles River Laboratories; Protagenic Therapeutics
- Class Antidepressants; Anxiolytics; Drug withdrawal therapies; Peptides
- Mechanism of Action Corticotropin releasing hormone inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Generalised anxiety disorder; Major depressive disorder; Opioid-related disorders; Post-traumatic stress disorders
- Preclinical Anxiety disorders; Depressive disorders; Impulse control disorders; Neurodegenerative disorders